Global Intravenous Immunoglobulin Market Forecast to Reach US$ 15,789.1 Mn , Rising Incidence of Immunodeficiency Diseases to Boost Growth: Fortune Business Insights

(The Express Wire via Comtex)

Intravenous Immunoglobulin (IVIG) Market Threats In The Target Market, Market Study of Revenue Details and Forecast By 2025

The global intravenous immunoglobulin market is likely to witness considerable growth driven by recent molecular advancements. According to a report published by Fortune Business Insights, titled “Intravenous Immunoglobulin Market Size, Share and Industry Analysis By Indication (Primary Immunodeficiency, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Guillain-Barré Syndrome (GBS), Immune Thrombocytopenic Purpura (ITP), Multifocal Motor Neuropathy (MMN)), Form (Liquid, Lyophilized), End User (Hospitals, Clinics, Homecare) and Regional Forecast, 2018 2025,” the was valued at USD 9,787.6 Million in 2017 and is projected to reach USD 15,789.1 Million by 2025 exhibiting a CAGR of 6.2% in the forecast period (2018-2025).

Intravenous immunoglobulin is a blood product prepared from the serum of a particular range. It is mostly used for treatment of patients with major antibody deficiencies. They are categorized as glycoprotein molecules manufactured by plasma or white blood cells (WBC). These products are used to enhance the immune system by binding specific antigens such as bacteria and virus. As a result, they cater to patients with a weaker or exposed immune system. Intravenous immunoglobulins are the type of drugs that are directly administered to the veins through syringes. The intravenous route is preferred n critical and bed-ridden patients, that have a lesser effect through oral or other modes. The proven efficiency of these drugs will lead to high product adoption across the world.

Browse Complete Report [email protected] https://www.fortunebusinessinsights.com/industry-reports/intravenous-immunoglobulins-market-100593

Increasing Adoption of Immunoglobulins to Help Asia Pacific Register Fastest Growth

According to the report, The Global Intravenous Immunoglobulin Market was dominated by North America with a market value of US$ 5,587.4 Mn in 2017. The region is likley to remain dominant through the forecast period as well due to the presence of first line treatment for critical immune disorders. Other factors boosting the market in the region are rising number of patients and efficient results of the intravenous immunoglobulin treatment.

On the other side, the market in Asia Pacific is anticipated to grpow at faster rate in the coming years on account of the rise in awareness about the treatment option avaiulable for immunologic deficiencies. In addition to this, the rise in adoption and expenditure of immunoglobulins in economies such as Japan, China,and Indiais anticipated to boost the market in the region.

Key Segmentation:

By Indication

  • Primary Immunodeficiency
  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
  • Guillain-Barré Syndrome (GBS)
  • Immune Thrombocytopenic Purpura (ITP)
  • Multifocal Motor Neuropathy (MMN)
  • Others

By Form

  • Liquid
  • Lyophilized

By End User

  • Hospitals
  • Clinics
  • Homecare

By Geography

  • North America (the U.S., and Canada)
  • Europe (Germany, U.K., France, Italy, Spain, Scandinavia, and Rest of Europe)
  • Asia Pacific (China, India, Japan, Australia, South East Asia, and Rest of Asia Pacific)
  • Latin America (Brazil, Mexico, and Rest of Latin America
  • Middle East and Africa (GCC, South Africa, and Rest of Middle East and Africa)

Get PDF Brochure of this [email protected] https://www.fortunebusinessinsights.com/enquiry/sample/intravenous-immunoglobulins-market-100593

Some major points from Table of Content:

1. Introduction

1.1.Research Scope

1.2.Market Segmentation

1.3.Research Methodology

1.4.Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

3.1.Market Drivers

3.2.Market Restraints

3.3.Market Opportunities

4. Key Insights

4.1.Pipeline Analysis

4.2.Overview of Regulatory Scenario by Key Regions

4.3.Key Industry Developments

4.4.Number (Estimated) of Primary Immunodeficiency (PI) Patients by Key Countries

4.5.Overview of Reimbursement Scenario

5. Global Intravenous Immunoglobulin Market Analysis, Insights and Forecast, 2015-2025

5.1.Key Findings /Summary

5.2.Market Analysis, Insights and Forecast By Indication

5.2.1.Primary Immunodeficiency

5.2.2.Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

5.2.3.Guillain-Barré Syndrome (GBS)

5.2.4.Immune Thrombocytopenic Purpura (ITP)

5.2.5.Multifocal Motor Neuropathy (MMN)

5.2.6.Others

5.3.Market Analysis, Insights and Forecast By Form

5.3.1.Liquid

5.3.2.Lyophilized

5.4.Market Analysis, Insights and Forecast By End User

5.4.1.Hospitals

5.4.2.Clinics

5.4.3.Homecare

5.5.Market Analysis, Insights and Forecast By Region

5.5.1.North America

5.5.2.Europe

5.5.3.Asia Pacific

5.5.4.Latin America

5.5.5.Middle East and Africa

Continued...

Grifols, S.A., Leading Market with Better Product Offerings

Analysts at Fortune Business Insights foresees the Grifols, S.A., to emerge as the dominant player in the global market for intravenous immunoglobulin market. This is because this company was leading the market in the year 2017 as well, all because oftheir product offerings and the usual route of administration, whioch ultimately dominated a considerate proportion of share ion the market. Besides this, Grifols, S.A., accounts for largest revenues from well developed regions namely Europe and North America.

Other companies operating in the global iontravenous immunoglobulin market are Bio Products Laboratory Ltd., Kedrion S.p.A, Grifols, S.A., Biotest AG, China Biologic Products Holdings, Inc., Octapharma, and CSL Behring.

Secondary Data Sources That We Refer To

  • Annual reports, investor presentation, SEC filings, and press releases of companies operating in the market
  • Studies published by relevant associations MedTech Europe; American College of Radiology; Cancer Council Australia; Japan Hospital Association, etc.), government sources (Centers for Disease Control and Prevention, Ministry of Health, Labour and Welfare, Japan; National Health Service, England, etc.), international organizations (World Health Organization, The Organization for Economic Co-operation and Development, Eurostat, etc.), and articles published by Research Gate, NCBI, etc.
  • Website, reports, and press releases of end user facilities Hospitals, Ambulatory Surgery Centres, Clinics
  • Industry journals and paid databases

More Trending Topics From Fortune Business [email protected]

Orthopedic Implants Market Size, Growth, Trends | Analysis Report 2026

Urinary Catheter Market Size, Share, Trends | Global Report 2026

About us:

Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights we aim at highlighting the most lucrative growth opportunities for our clients. We therefore offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

Press Release Distributed by The Express Wire

To view the original version on The Express Wire visit Global Intravenous Immunoglobulin Market Forecast to Reach US$ 15,789.1 Mn , Rising Incidence of Immunodeficiency Diseases to Boost Growth: Fortune Business Insights